Elezaby Aly, Dexheimer Ryan, Sallam Karim
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, United States.
Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, CA, United States.
Front Cardiovasc Med. 2022 Sep 21;9:981838. doi: 10.3389/fcvm.2022.981838. eCollection 2022.
Immunosuppressive medications are widely used to treat patients with neoplasms, autoimmune conditions and solid organ transplants. Key drug classes, namely calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and purine synthesis inhibitors, have direct effects on the structure and function of the heart and vascular system. In the heart, immunosuppressive agents modulate cardiac hypertrophy, mitochondrial function, and arrhythmia risk, while in vasculature, they influence vessel remodeling, circulating lipids, and blood pressure. The aim of this review is to present the preclinical and clinical literature examining the cardiovascular effects of immunosuppressive agents, with a specific focus on cyclosporine, tacrolimus, sirolimus, everolimus, mycophenolate, and azathioprine.
免疫抑制药物广泛用于治疗肿瘤、自身免疫性疾病患者以及实体器官移植患者。主要药物类别,即钙调神经磷酸酶抑制剂、雷帕霉素靶蛋白(mTOR)抑制剂和嘌呤合成抑制剂,对心脏和血管系统的结构与功能有直接影响。在心脏方面,免疫抑制剂可调节心脏肥大、线粒体功能和心律失常风险,而在血管系统中,它们会影响血管重塑、循环脂质和血压。本综述的目的是呈现检验免疫抑制剂心血管效应的临床前和临床文献,特别关注环孢素、他克莫司、西罗莫司、依维莫司、霉酚酸酯和硫唑嘌呤。